Radiance to start RAPID (Radiation After PTA is Done) RDX trial:
This article was originally published in Clinica
Executive Summary
Radiance Medical Systems is to begin a clinical trial in the US to assess its RDX radiation delivery system as a means of preventing restenosis in the peripheral vasculature. The RAPID (Radiation After PTA is Done) trial is part of an international study, already underway in Europe, designed to enrol up to 50 patients. The RDX system will be used to treat the superficial femoral artery, popliteal arteries and the primary arteries of the middle and lower leg. The study will include both de novo and in-stent lesion, says the Irvine, California firm.